SeaStar Medical Q1 net revenue rises to $293K; net loss narrows to $3.8M

SeaStar Medical Holding Corp

2025-Q1 EPS reported -$0.44 revenue$293,000

Net product revenue ~$293K, a four-fold increase from Q4 2024's $68K.
Net loss of $3.8M ($0.44/share) vs $12.7M ($4.73/share) a year ago.
NEUTRALIZE-AKI trial 50% enrolled; interim analysis by DSMB expected Q3 2025.
Two new Breakthrough Device Designations for SCD therapy in cardiac surgery (adult & ped).
Cash $5.3M as of March 31, 2025 vs $1.8M Dec 31, 2024; $6M offering closed Jan 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.